Click here to take the CME Evaluation and Post-Meeting Survey
Dr. Gulick’s research interests include designing, conducting, and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention and assess agents with new mechanisms of action. He currently serves as Principal Investigator of the Cornell-New Jersey HIV Clinical Trials Unit of the ACTG and the HIV Prevention Trials Network (HPTN), sponsored by the NIH.
He also serves as the Co-Chair of the U.S. Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection, a Member of the NIH Office of AIDS Research Advisory Committee, and is a Board Member of the International Antiviral Society-USA. He is a Member of the American Society of Clinical Investigation, the Association of American Physicians, International AIDS Society, and the Infectious Diseases Society of America, and has presented at national and international meetings and published widely.
At the completion of this educational session, learners will:
1. Understand new data on HIV treatment and prevention strategies.
2. Learn about new drugs for HIV treatment and prevention.
3. Discuss updates for SARS-CoV-2 and COVID-19.
This CME activity has approved for AMA PRA Category 1 Credit™
for March 24, 2021 as a live activity. This activity will also be available as an enduring activity from March 25, 2021, through March 23, 2024.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose.
- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.
- Dr. Gulick will support his presentation and clinical recommendations with the best available evidence from the medical literature and will submit his slides in advance for adequate peer review.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare
Click here to take the CME Evaluation and Post-Meeting Evaluation